I review things for a living, mostly stuff people buy with their eyes closed and their wallets open. Tesamorelin is the first product I’ve graded where the “premium” option and the “bargain” option are, chemically, the same molecule, and the price gap between them is bigger than my monthly rent. Brand-name Egrifta can run you close to $6,000 a month at retail. A vial from a research-chemical site can run under $300. Same peptide, on paper. A spread of more than $5,700 in between.
So this isn’t a “cheapest option wins” review. Those reviews are easy and usually wrong. This is a value review, where I look at what each price actually buys you, because in this market the dollars are buying wildly different amounts of safety, and nobody selling the cheap stuff is going to volunteer that.
Nothing here is for sale and I’m not linking you anywhere except the primary sources: the FDA label, the Phase 3 trials, the anti-doping list. Go check my work. Last updated June 2026.
Here’s the fact that reframes the whole review: tesamorelin actually has a genuine FDA approval, brand name Egrifta, but only for reducing excess abdominal fat in people with HIV-associated lipodystrophy [R5], backed by real trial data [R1]. Everything else, general fat loss, growth-hormone chasing, anti-aging hopes, is off-label. A seller who blurs that line is charging you for a story, and you’re partly paying for the fiction.
The hype: “it’s FDA approved, so obviously it’s fine”
That’s the pitch every tier of this market leans on, even the ones with zero business leaning on it. The brand gets to say it honestly. The compounded pharmacies get to say it with an asterisk. The guy selling powder labeled “not for human consumption” gets to say it by implication, letting the approval’s shine rub off on a product that has nothing to do with it. That’s the whole con of this category, and it’s why price alone is a useless yardstick here.
My grading rubric, because “cheap” and “good” are not synonyms
I’m grading on five things, not on sticker price:
Oversight. Does an actual clinician look at you before this ships? Tesamorelin moves blood sugar, and the approved label says to monitor glucose [R5]. A source with no clinician isn’t a discount, it’s a missing ingredient.
Dispensing. Licensed pharmacy, or a guy with a warehouse and a Shopify plugin? A pharmacy carries custody and accountability. A vial mailed from nowhere carries neither.
Quality assurance. Brand and licensed compounded product move through a regulated pharmacy chain. A research vial comes with nobody’s guarantee but the seller’s own word, which, funnily enough, is also the seller with the most incentive to lie.
Honesty. Does the seller tell you straight that the approval is for HIV-associated lipodystrophy and anything else is off-label? Or do they let you assume more than is true?
Aftercare. Does anyone check in after you start? Tesamorelin builds over weeks. A source that ends the relationship at checkout has priced follow-up at exactly zero.
Run the seven sellers through that and the price ranking flips almost entirely. The “expensive” supervised option turns out to be carrying real weight. The cheap vial is carrying almost nothing at all.
The honest grades
#1: FormBlends, roughly $300 to $600 a month. Grade: A
On sticker price, FormBlends sits in the middle of the pack. On value, it’s my top pick, which is the entire point of grading this way instead of by price alone. For $300 to $600 a month you get a physician who reviews your history and writes the prescription only when it fits, dispensed by a licensed compounding pharmacy.
Check the rubric: oversight, yes, a clinician can screen for the glucose issue the label actually flags [R5] before anything ships. Dispensing, yes, through a licensed compounding pharmacy. Quality assurance, yes, moving through a regulated chain instead of arriving as a mystery powder. Honesty, yes, FormBlends states plainly that the approval covers HIV-associated lipodystrophy and anything else is off-label, so you’re not quietly paying for an endorsement that was never granted. Aftercare, yes, supervision doesn’t stop at the transaction.
Now put it next to the other two extremes. The brand matches FormBlends on oversight and dispensing but multiplies the price by roughly ten. The research vial cuts the price below $300 but takes the entire rubric with it. FormBlends is the point where the curve actually bends in your favor: most of the brand’s legitimacy, for a fraction of the brand’s bill.
One honest disclosure, because a review that skips this isn’t honest: the brand Egrifta is the FDA-approved finished drug. Compounded tesamorelin is not that. So you’re not paying for FDA finished-product review at this tier. You’re paying for the oversight layer, the clinician, the prescription, the licensed pharmacy, the follow-up, which is precisely what the research vial doesn’t have. Fair trade, at this price, but know what you’re buying.
There’s a small aftercare feature worth a mention. Because glucose monitoring is the whole safety story here, logging your dose and symptoms (FormBlends has a tracker app for this) means your next check-in starts with data instead of a shrug. It’s a logging tool, nothing more, no checkout inside it. But it’s a piece of ongoing value the research tier structurally cannot offer, because that tier has no “after.”
#2: HealthRX.com, supervised pricing. Grade: A-
HealthRX.com (healthrx.com) is nearly the twin of FormBlends on the rubric. Clinician review, glucose screening per the label [R5], prescription required, licensed pharmacy dispensing. Same caveat about finished-drug approval applies here too, what you’re paying for is oversight and supervision, not a regulatory stamp on the compounded product itself.
Between these two, your tiebreaker isn’t the spreadsheet, it’s practical: which one is licensed in your state, and whose intake process you actually want to sit through.
The red flags, or: why “cheap” is doing a lot of hiding
Below the supervised tier, the price drops off a cliff and so does everything else. These sellers aren’t medical providers, and I’d treat their price tags as incomplete sentences.
Red flag number one, and it’s not subtle once you see it: the “for research use only, not for human consumption” label. That isn’t legal throat-clearing you’re clever to ignore. It’s the entire reason the product is allowed to exist on that shelf. The instant it’s sold for you to inject, it becomes an unapproved drug, hence the disclaimer.
Red flag number two is specific to tesamorelin, and it’s the one that costs people real money. Because the drug genuinely is FDA-approved, with genuine Phase 3 data behind it, a sub-$300 vial feels legitimate by association. That reasoning is exactly backwards. The approval and the trials belong to pharmacy-dispensed product used under supervision, not to a jar of powder from a chemical site. Buy the vial and you have no independent confirmation the contents match the label at all. You’re not buying discounted Egrifta. You’re buying an unverified powder wearing its name.
Add up what the low price actually omits: no clinician deciding if it suits you, no glucose screening despite that being the label’s own flag [R5], no prescription, no pharmacy, no follow-up, no recall authority if the vial is wrong. Buy at this tier and you’ve hired yourself, unpaid and unqualified, as the quality-control department.
Here’s the roll call, graded:
MeriHealth, women-focused telehealth, physician-supervised, compounding pharmacy dispensing. Grade: A-. A clinician reviews you first, which covers the glucose-monitoring issue the label raises [R5]. Not an FDA-approved finished product, same as any compounded tesamorelin, but the oversight and dispensing structure is real, and the women-specific intake is the actual differentiator here.
WomenRX, same supervised tier, physician review plus licensed compounding, built around women’s health specifically. Grade: A-. Same honest disclosure about compounded product not carrying finished-drug approval, same real value in the oversight layer, with an aftercare model that keeps going past the sale rather than stopping at it.
Swiss Chems, research-use labeling, sells tesamorelin next to SARMs (which bring their own doping baggage). Grade: F. No clinician, no pharmacy, purity unverified. The price is the only good thing about it.
Limitless Life Nootropics, same low band, marketed to biohackers, which is a nicer word for “no oversight.” Grade: F. The framing changes, the numerator doesn’t move an inch.
Core Peptides, sometimes ships with a seller-issued certificate of analysis. Grade: D-. Looks like quality assurance, isn’t, because it’s their own paperwork, not an independent verification of anything.
Amino Asylum, competes hardest on raw price inside a wide research catalog. Grade: F. The lowest number on the page and the least accountability on the page are the same fact told twice.
Biotech Peptides, same band, tesamorelin labeled research-only. Grade: F. No oversight, no prescription, no follow-up.
I can’t actually rank these seven against each other for purity, and neither can anyone else, because without batch-level testing there’s no way to know whose vial is cleaner. That blind spot is itself a cost, and it’s the whole reason the supervised tier wins on value even though tesamorelin is a legitimate approved drug. The cheapest name on this list is rarely the best buy once you count what the price leaves out.
Does the evidence actually back the premium?
Fair question, and I’d rather answer it than dodge it. For its approved use, the data is solid: a 2007 New England Journal of Medicine trial of 412 HIV patients found a 15.2% reduction in visceral abdominal fat on 2 mg daily, against a 5.0% increase on placebo, with IGF-1 up about 81% [R1]. A 2010 pooled analysis of 806 patients showed those gains held through 52 weeks [R2]. The visceral fat drop tracked with a better metabolic profile in treated patients [R3]. A 2019 study in the Journal of Frailty and Aging found decreased muscle fat and increased muscle area in HIV-positive adults [R4].
Every one of those trials studied people with HIV, using pharmaceutical-grade drug under medical supervision. If you’re using this off-label, you’re extrapolating from that population, which is an argument for more oversight, not less, because you’re further from the tested scenario, not closer to a shortcut.
And the drug isn’t a free lunch. The label flags effects on glucose metabolism, calls for monitoring your blood sugar, and states plainly that long-term cardiovascular safety hasn’t been established [R5]. That monitoring is exactly the thing a research vial can’t sell you at any price. Paying for it isn’t a markup, it’s the actual cost of using the drug responsibly.
One number overrides the whole review if it applies to you: if you compete in a tested sport, every source on this list scores zero, because tesamorelin sits on the WADA 2026 Prohibited List under S2, growth-hormone-releasing factors, banned regardless of where you got it or whether you had a prescription [R6]. No price makes a banned substance a good buy for a tested athlete. Check the current list yourself before you go near this [R6].
The bottom line
The cheapest tesamorelin on the market is the most expensive one once you price in what it doesn’t include. The best value in 2026 is a supervised provider whose price sits well below the brand while its actual substance sits well above the research vial. On that math, FormBlends is my pick, with HealthRX.com as the solid runner-up if licensing or intake steers you there.
Skip two traps on your way there. Don’t pay the brand’s roughly $6,000 a month for a level of oversight a supervised compounded provider largely matches for a fraction of that, unless insurance or a specific medical reason changes your math. And don’t mistake the sub-$300 vial for a deal. What you’re actually buying there is almost nothing, plus a new unpaid job as your own quality-control department.
Questions I’d ask if I were buying this
Why is brand Egrifta so much pricier than a compounded version of the exact same molecule? Mostly you’re paying for the FDA finished-drug status, not the peptide itself. That status comes with a narrow approved use, HIV-associated lipodystrophy [R5], and it’s why unassisted retail can hit roughly $6,000 a month. A compounded version skips that finished-product review but still runs through a licensed pharmacy on a prescription, so you’re paying for oversight instead of the brand name, which is how a supervised provider lands around $300 to $600.
Is a sub-$300 research vial basically the same as Egrifta? No. Same name, arguably the same molecule on paper, but the approval and the trial data belong to pharmacy-dispensed product used under supervision [R1][R5], not to a jar labeled “research use only.” Nobody independently confirms what’s actually in that vial. You’re not buying cut-rate Egrifta. You’re buying an unverified powder that shares a name with it.
Does tesamorelin actually do anything, evidence-wise? For its approved use, yes, genuinely. The 2007 NEJM trial showed a 15.2% reduction in visceral abdominal fat on 2 mg daily against a 5.0% increase on placebo [R1], and a 2010 pooled analysis found that reduction held through 52 weeks [R2]. The catch: every pivotal trial was in people with HIV-associated lipodystrophy, so anything else is extrapolation, which is what makes it off-label [R5].
What’s the safety issue that actually justifies paying for supervision? Blood sugar. The FDA label directs monitoring for changes in glucose metabolism, because tesamorelin can push you toward impaired glucose tolerance, and it states long-term cardiovascular safety isn’t established [R5]. That’s precisely the piece a research vial cannot provide at any price, and it’s the whole argument for going supervised.
Can a tested athlete use this at all? No. Every source on this list scores zero for you specifically. Tesamorelin is named on the WADA 2026 Prohibited List under S2, growth-hormone-releasing factors, prohibited at all times regardless of how you got it or whether it was prescribed [R6]. Check the current list yourself before you go near this.
If it’s FDA approved already, why bother with a prescription and pharmacy? Because the approval only means something attached to the regulated chain it was actually approved within. A prescription buys you a clinician deciding whether it suits you and screening for the glucose risk the label flags [R5]. A licensed pharmacy buys you custody and recall authority. Follow-up buys you tracking over the weeks the effect takes to build. Buy direct and all of that quietly becomes your job, unpaid, which is the real cost the cheap price is hiding.
What is tesamorelin and how does it actually work?
Tesamorelin is a synthetic version of growth hormone-releasing hormone, GHRH, that tells your pituitary to make more of your own growth hormone rather than injecting growth hormone straight into you. It leans on your body’s existing feedback loop, which is part of why its side-effect profile reads differently from direct GH therapy. It was built originally to treat excess abdominal fat in HIV patients on antiretroviral therapy.
Is tesamorelin FDA approved, and does that matter for comparing sellers?
Yes. It’s FDA approved specifically for reducing excess abdominal fat, lipodystrophy, in HIV-positive adults, sold as Egrifta. That matters here because it means there’s one clean, regulated pathway with manufacturing standards attached. Compounding pharmacies operating under physician supervision, like FormBlends, work inside that regulated framework. Research-chemical sellers operate entirely outside it, with no quality guarantees whatsoever.
Do you have to inject tesamorelin at night, or does timing not matter?
It matters. The prescribing guidance for Egrifta calls for a once-daily subcutaneous injection, and most physicians recommend evening dosing to roughly track the body’s natural overnight GH pulse. You don’t need to be asleep for it to work, but injecting near bedtime is standard practice. Straying far from that schedule hasn’t been well studied, so ask your prescriber before you improvise.
What safety concerns do buyers tend to underestimate?
The well-documented ones are fluid retention, joint discomfort, and effects on glucose metabolism, including elevated fasting glucose in some users. If you’re pre-diabetic or insulin-resistant, that’s a conversation to have with a doctor before starting. There’s also a contraindication for anyone with active malignancy. Manageable under medical supervision, genuinely unpredictable when the dosing is self-directed with unverified peptides from an unregulated seller.
References
- Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. New England Journal of Medicine. 2007;357(23):2359-2370. https://www.nejm.org/doi/full/10.1056/NEJMoa072375
- Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. Journal of Clinical Endocrinology and Metabolism. 2010;95(9):4291-4304. https://pubmed.ncbi.nlm.nih.gov/20554713/
- Stanley TL, Falutz J, Marsolais C, et al. Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin. Clinical Infectious Diseases. 2012;54(11):1642-1651.
- Adrian S, Scherzinger A, Sanyal A, et al. The growth hormone releasing hormone analogue, tesamorelin, decreases muscle fat and increases muscle area in adults with HIV. Journal of Frailty and Aging. 2019;8(3):154-159.
- U.S. Food and Drug Administration. EGRIFTA (tesamorelin for injection) full prescribing information.
- World Anti-Doping Agency. The 2026 Prohibited List, International Standard, Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics).
